{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:04:11Z","timestamp":1789416251994,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple genetic aberrations in the regulation of BCL6, including in acetyltransferase genes, occur in clinically aggressive B-cell lymphomas and lead to higher expression levels and activity of this transcriptional repressor. BCL6 is, therefore, an attractive target for therapy in aggressive lymphomas. In this study romidepsin, a potent histone deacetylase inhibitor (HDACi), induced apoptosis and cell cycle arrest in Burkitt and diffuse large B-cell lymphoma cell lines, which are model cells for studying the mechanism of action of BCL6. Romidepsin caused BCL6 acetylation at early timepoints inhibiting its function, while at later timepoints BCL6 expression was reduced and target gene expression increased due to chromatin modification. MYC contributes to poor prognosis in aggressive lymphoma. MYC function is reduced by inhibition of chromatin readers of the bromodomain and extra-terminal repeat (BET) family, which includes BRD4. The novel combination of romidepsin and JQ1, a BRD4 inhibitor was investigated and showed synergy. Collectively we suggest that the combination of HDACi and BRD4i should be pursued in further pre-clinical testing.<\/jats:p>","DOI":"10.1038\/s41598-019-52714-4","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T11:03:16Z","timestamp":1573470196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells"],"prefix":"10.1038","volume":"9","author":[{"given":"Mar\u00eda G.","family":"Cortiguera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Garc\u00eda-Gaipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Batlle-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dolores","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"key":"52714_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375\u20132390 (2016).","journal-title":"Blood"},{"key":"52714_CR2","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier, B. et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood 116, 2040\u20132045 (2010).","journal-title":"Blood"},{"key":"52714_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nri3814","volume":"15","author":"K Basso","year":"2015","unstructured":"Basso, K. & Dalla-Favera, R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol 15, 172\u2013184 (2015).","journal-title":"Nat Rev Immunol"},{"key":"52714_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1126\/science.276.5312.589","volume":"276","author":"AL Dent","year":"1997","unstructured":"Dent, A. L., Shaffer, A. L., Yu, X., Allman, D. & Staudt, L. M. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 276, 589\u2013592 (1997).","journal-title":"Science"},{"key":"52714_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng0697-161","volume":"16","author":"BH Ye","year":"1997","unstructured":"Ye, B. H. et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet 16, 161\u2013170 (1997).","journal-title":"Nat Genet"},{"key":"52714_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ccr.2005.03.037","volume":"7","author":"G Cattoretti","year":"2005","unstructured":"Cattoretti, G. et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7, 445\u2013455 (2005).","journal-title":"Cancer Cell"},{"key":"52714_CR7","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1182\/blood-2002-11-3387","volume":"101","author":"L Pasqualucci","year":"2003","unstructured":"Pasqualucci, L. et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 101, 2914\u20132923 (2003).","journal-title":"Blood"},{"key":"52714_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.molmed.2014.03.001","volume":"20","author":"K Hatzi","year":"2014","unstructured":"Hatzi, K. & Melnick, A. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends Mol Med 20, 343\u2013352 (2014).","journal-title":"Trends Mol Med"},{"key":"52714_CR9","first-page":"2732","volume":"53","author":"BH Ye","year":"1993","unstructured":"Ye, B. H., Rao, P. H., Chaganti, R. S. & Dalla-Favera, R. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer research 53, 2732\u20132735 (1993).","journal-title":"Cancer research"},{"key":"52714_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1158\/1078-0432.CCR-16-2071","volume":"23","author":"MG Cardenas","year":"2017","unstructured":"Cardenas, M. G. et al. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. Clin Cancer Res 23, 885\u2013893 (2017).","journal-title":"Clin Cancer Res"},{"key":"52714_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08420.x","volume":"152","author":"SD Wagner","year":"2011","unstructured":"Wagner, S. D., Ahearne, M. & Ko Ferrigno, P. The role of BCL6 in lymphomas and routes to therapy. Br J Haematol 152, 3\u201312 (2011).","journal-title":"Br J Haematol"},{"key":"52714_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/14728222.2018.1420782","volume":"22","author":"RJ Leeman-Neill","year":"2018","unstructured":"Leeman-Neill, R. J. & Bhagat, G. BCL6 as a therapeutic target for lymphoma. Expert opinion on therapeutic targets 22, 143\u2013152 (2018).","journal-title":"Expert opinion on therapeutic targets"},{"key":"52714_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/imr.12745","volume":"288","author":"L Pasqualucci","year":"2019","unstructured":"Pasqualucci, L. Molecular pathogenesis of germinal center-derived B cell lymphomas. Immunological reviews 288, 240\u2013261 (2019).","journal-title":"Immunological reviews"},{"key":"52714_CR14","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1084\/jem.20100204","volume":"207","author":"AY Lai","year":"2010","unstructured":"Lai, A. Y. et al. DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas. The Journal of experimental medicine 207, 1939\u20131950 (2010).","journal-title":"The Journal of experimental medicine"},{"key":"52714_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/onc.2013.535","volume":"34","author":"A Batlle-Lopez","year":"2015","unstructured":"Batlle-Lopez, A. et al. Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus. Oncogene 34, 246\u2013256 (2015).","journal-title":"Oncogene"},{"key":"52714_CR16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.18632\/oncoscience.239","volume":"2","author":"A Batlle-Lopez","year":"2015","unstructured":"Batlle-Lopez, A., Cortiguera, M. G. & Delgado, M. D. The epigenetic regulator CTCF modulates BCL6 in lymphoma. Oncoscience 2, 783\u2013784 (2015).","journal-title":"Oncoscience"},{"key":"52714_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson, M. A. & Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12\u201327 (2012).","journal-title":"Cell"},{"key":"52714_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev-med-111314-035900","volume":"67","author":"N Ahuja","year":"2016","unstructured":"Ahuja, N., Sharma, A. R. & Baylin, S. B. Epigenetic Therapeutics: A New Weapon in the War Against Cancer. Annual review of medicine 67, 73\u201389 (2016).","journal-title":"Annual review of medicine"},{"key":"52714_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","volume":"6","author":"M New","year":"2012","unstructured":"New, M., Olzscha, H. & La Thangue, N. B. HDAC inhibitor-based therapies: can we interpret the code? Molecular oncology 6, 637\u2013656 (2012).","journal-title":"Molecular oncology"},{"key":"52714_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/ng1018","volume":"32","author":"OR Bereshchenko","year":"2002","unstructured":"Bereshchenko, O. R., Gu, W. & Dalla-Favera, R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 32, 606\u2013613 (2002).","journal-title":"Nat Genet"},{"key":"52714_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West, A. C. & Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. The Journal of clinical investigation 124, 30\u201339 (2014).","journal-title":"The Journal of clinical investigation"},{"key":"52714_CR22","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-14-2555","volume":"21","author":"SE Bates","year":"2015","unstructured":"Bates, S. E., Robey, R. W. & Piekarz, R. L. CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio. Clin Cancer Res 21, 2195\u20132197 (2015).","journal-title":"Clin Cancer Res"},{"key":"52714_CR23","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","volume":"118","author":"M Kalac","year":"2011","unstructured":"Kalac, M. et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 118, 5506\u20135516 (2011).","journal-title":"Blood"},{"key":"52714_CR24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3324\/haematol.2013.091827","volume":"99","author":"SM Aukema","year":"2014","unstructured":"Aukema, S. M. et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica 99, 726\u2013735 (2014).","journal-title":"Haematologica"},{"key":"52714_CR25","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1182\/blood-2012-05-428466","volume":"120","author":"M Gupta","year":"2012","unstructured":"Gupta, M. et al. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab\/R-CHOP. Blood 120, 4400\u20134406 (2012).","journal-title":"Blood"},{"key":"52714_CR26","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904\u2013917 (2011).","journal-title":"Cell"},{"key":"52714_CR27","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067\u20131073 (2010).","journal-title":"Nature"},{"key":"52714_CR28","first-page":"75","volume":"5","author":"MG Cortiguera","year":"2015","unstructured":"Cortiguera, M. G., Batlle-L\u00f3pez, A., Albajar, M., Delgado, M. D. & Le\u00f3n, J. MYC as therapeutic target in leukemia and lymphoma. Blood and Lymphatic. Cancer: Targets and Therapy 5, 75\u201379 (2015).","journal-title":"Cancer: Targets and Therapy"},{"key":"52714_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ddtec.2016.06.004","volume":"19","author":"G Andrieu","year":"2016","unstructured":"Andrieu, G., Belkina, A. C. & Denis, G. V. Clinical trials for BET inhibitors run ahead of the science. Drug discovery today. Technologies 19, 45\u201350 (2016).","journal-title":"Drug discovery today. Technologies"},{"key":"52714_CR30","first-page":"4460","volume":"63","author":"MJ Peart","year":"2003","unstructured":"Peart, M. J. et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer research 63, 4460\u20134471 (2003).","journal-title":"Cancer research"},{"key":"52714_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1182\/blood.V80.2.459.459","volume":"80","author":"J Finke","year":"1992","unstructured":"Finke, J. et al. Expression of bcl-2 in Burkitt\u2019s lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood 80, 459\u2013469 (1992).","journal-title":"Blood"},{"key":"52714_CR32","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.4161\/cc.25914","volume":"12","author":"C Ierano","year":"2013","unstructured":"Ierano, C. et al. Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors. Cell Cycle 12, 2829\u20132838 (2013).","journal-title":"Cell Cycle"},{"key":"52714_CR33","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1158\/1535-7163.MCT-07-2256","volume":"7","author":"A Newbold","year":"2008","unstructured":"Newbold, A. et al. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 7, 1066\u20131079 (2008).","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 1","key":"52714_CR34","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1007\/s10637-010-9591-3","volume":"28","author":"J Zain","year":"2010","unstructured":"Zain, J. & O\u2019Connor, O. A. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Investigational new drugs 28(Suppl 1), S58\u201378 (2010).","journal-title":"Investigational new drugs"},{"key":"52714_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1074-7613(00)00020-0","volume":"13","author":"AL Shaffer","year":"2000","unstructured":"Shaffer, A. L. et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13, 199\u2013212 (2000).","journal-title":"Immunity"},{"key":"52714_CR36","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1038\/sj.onc.1203864","volume":"19","author":"M Kikuchi","year":"2000","unstructured":"Kikuchi, M. et al. Identification of negative regulatory regions within the first exon and intron of the BCL6 gene. Oncogene 19, 4941\u20134945 (2000).","journal-title":"Oncogene"},{"key":"52714_CR37","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1073\/pnas.232581199","volume":"99","author":"X Wang","year":"2002","unstructured":"Wang, X., Li, Z., Naganuma, A. & Ye, B. H. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America 99, 15018\u201315023 (2002).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"52714_CR38","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1200\/JCO.2005.14.498","volume":"23","author":"AM Melnick","year":"2005","unstructured":"Melnick, A. M., Adelson, K. & Licht, J. D. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? J Clin Oncol 23, 3957\u20133970 (2005).","journal-title":"J Clin Oncol"},{"key":"52714_CR39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.immuni.2016.08.012","volume":"45","author":"KL Bunting","year":"2016","unstructured":"Bunting, K. L. et al. Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. Immunity 45, 497\u2013512 (2016).","journal-title":"Immunity"},{"key":"52714_CR40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ccr.2009.12.050","volume":"17","author":"LC Cerchietti","year":"2010","unstructured":"Cerchietti, L. C. et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17, 400\u2013411 (2010).","journal-title":"Cancer Cell"},{"key":"52714_CR41","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1172\/JCI85795","volume":"126","author":"MG Cardenas","year":"2016","unstructured":"Cardenas, M. G. et al. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. The Journal of clinical investigation 126, 3351\u20133362 (2016).","journal-title":"The Journal of clinical investigation"},{"key":"52714_CR42","first-page":"769","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nature reviews 5, 769\u2013784 (2006).","journal-title":"Nature reviews"},{"key":"52714_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/cdd.2016.105","volume":"24","author":"V Peperzak","year":"2017","unstructured":"Peperzak, V., Slinger, E., Ter Burg, J. & Eldering, E. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. Cell Death Differ 24, 111\u2013119 (2017).","journal-title":"Cell Death Differ"},{"key":"52714_CR44","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.V86.5.1903.bloodjournal8651903","volume":"86","author":"AJ Minn","year":"1995","unstructured":"Minn, A. J., Rudin, C. M., Boise, L. H. & Thompson, C. B. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86, 1903\u20131910 (1995).","journal-title":"Blood"},{"key":"52714_CR45","doi-asserted-by":"publisher","first-page":"16090","DOI":"10.1073\/pnas.0505585102","volume":"102","author":"Y Zhao","year":"2005","unstructured":"Zhao, Y. et al. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proceedings of the National Academy of Sciences of the United States of America 102, 16090\u201316095 (2005).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"52714_CR46","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/leu.2016.357","volume":"31","author":"H Ding","year":"2017","unstructured":"Ding, H. et al. Histone deacetylase inhibitors interrupt HSP90*RASGRP1 and HSP90*CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells. Leukemia 31, 1593\u20131602 (2017).","journal-title":"Leukemia"},{"key":"52714_CR47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ni.2527","volume":"14","author":"V Peperzak","year":"2013","unstructured":"Peperzak, V. et al. Mcl-1 is essential for the survival of plasma cells. Nat Immunol 14, 290\u2013297 (2013).","journal-title":"Nat Immunol"},{"key":"52714_CR48","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1182\/blood-2013-02-485441","volume":"122","author":"JE Amengual","year":"2013","unstructured":"Amengual, J. E. et al. Sirtuin and pan-class I\/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood 122, 2104\u20132113 (2013).","journal-title":"Blood"},{"key":"52714_CR49","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1038\/emboj.2012.155","volume":"31","author":"IDR Revilla","year":"2012","unstructured":"Revilla, I. D. R. et al. The B-cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis. EMBO J 31, 3130\u20133146 (2012).","journal-title":"EMBO J"},{"key":"52714_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.immuni.2006.02.003","volume":"24","author":"KP Nera","year":"2006","unstructured":"Nera, K. P. et al. Loss of Pax5 promotes plasma cell differentiation. Immunity 24, 283\u2013293 (2006).","journal-title":"Immunity"},{"key":"52714_CR51","doi-asserted-by":"publisher","first-page":"E2721","DOI":"10.1073\/pnas.1406722111","volume":"111","author":"J Bhadury","year":"2014","unstructured":"Bhadury, J. et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proceedings of the National Academy of Sciences of the United States of America 111, E2721\u20132730 (2014).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"52714_CR52","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/nm.3952","volume":"21","author":"PK Mazur","year":"2015","unstructured":"Mazur, P. K. et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature medicine 21, 1163\u20131171 (2015).","journal-title":"Nature medicine"},{"key":"52714_CR53","doi-asserted-by":"publisher","first-page":"6334","DOI":"10.1093\/nar\/gkx212","volume":"45","author":"VK Mishra","year":"2017","unstructured":"Mishra, V. K. et al. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Nucleic acids research 45, 6334\u20136349 (2017).","journal-title":"Nucleic acids research"},{"key":"52714_CR54","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.canlet.2018.04.032","volume":"428","author":"JC Enssle","year":"2018","unstructured":"Enssle, J. C. et al. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. Cancer Lett 428, 160\u2013172 (2018).","journal-title":"Cancer Lett"},{"key":"52714_CR55","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/jcmm.13059","volume":"21","author":"S Jostes","year":"2017","unstructured":"Jostes, S. et al. The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo. J Cell Mol Med 21, 1300\u20131314 (2017).","journal-title":"J Cell Mol Med"},{"key":"52714_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-017-0434-3","volume":"10","author":"AS Holscher","year":"2018","unstructured":"Holscher, A. S., Schulz, W. A., Pinkerneil, M., Niegisch, G. & Hoffmann, M. J. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines. Clinical epigenetics 10, 1 (2018).","journal-title":"Clinical epigenetics"},{"key":"52714_CR57","doi-asserted-by":"publisher","first-page":"33623","DOI":"10.18632\/oncotarget.5601","volume":"6","author":"G Borbely","year":"2015","unstructured":"Borbely, G., Haldosen, L. A., Dahlman-Wright, K. & Zhao, C. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. Oncotarget 6, 33623\u201333635 (2015).","journal-title":"Oncotarget"},{"key":"52714_CR58","doi-asserted-by":"publisher","first-page":"21507","DOI":"10.18632\/oncotarget.4242","volume":"6","author":"A Heinemann","year":"2015","unstructured":"Heinemann, A. et al. Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget 6, 21507\u201321521 (2015).","journal-title":"Oncotarget"},{"key":"52714_CR59","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.18632\/oncotarget.1873","volume":"5","author":"M Loosveld","year":"2014","unstructured":"Loosveld, M. et al. Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL. Oncotarget 5, 3168\u20133172 (2014).","journal-title":"Oncotarget"},{"key":"52714_CR60","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neo.2018.11.006","volume":"21","author":"L Zhao","year":"2019","unstructured":"Zhao, L., Okhovat, J. P., Hong, E. K., Kim, Y. H. & Wood, G. S. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma. Neoplasia 21, 82\u201392 (2019).","journal-title":"Neoplasia"},{"key":"52714_CR61","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1111\/cas.14102","volume":"110","author":"S Liu","year":"2019","unstructured":"Liu, S. et al. BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo. Cancer Sci 110, 2493\u20132506 (2019).","journal-title":"Cancer Sci"},{"key":"52714_CR62","doi-asserted-by":"crossref","unstructured":"Delgado, M. D., Albajar, M., Gomez-Casares, M. T., Batlle, A. & Leon, J. MYC oncogene in myeloid neoplasias. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 15, 87\u201394 (2013).","DOI":"10.1007\/s12094-012-0926-8"},{"key":"52714_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in enzyme regulation 22, 27\u201355 (1984).","journal-title":"Advances in enzyme regulation"},{"key":"52714_CR64","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","volume":"9","author":"M Albajar","year":"2011","unstructured":"Albajar, M. et al. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. Molecular cancer research: MCR 9, 564\u2013576 (2011).","journal-title":"Molecular cancer research: MCR"},{"key":"52714_CR65","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1309\/AJCP6XVEZU8EXLUG","volume":"133","author":"M Colorado","year":"2010","unstructured":"Colorado, M. et al. Simultaneous cytomorphologic and multiparametric flow cytometric analysis on lymph node samples is faster than and as valid as histopathologic study to diagnose most non-Hodgkin lymphomas. Am J Clin Pathol 133, 83\u201391 (2010).","journal-title":"Am J Clin Pathol"},{"key":"52714_CR66","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1242\/jcs.02890","volume":"119","author":"V Torrano","year":"2006","unstructured":"Torrano, V. et al. Targeting of CTCF to the nucleolus inhibits nucleolar transcription through a poly(ADP-ribosyl)ation-dependent mechanism. Journal of cell science 119, 1746\u20131759 (2006).","journal-title":"Journal of cell science"},{"key":"52714_CR67","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.18632\/oncotarget.2100","volume":"5","author":"JM Caraballo","year":"2014","unstructured":"Caraballo, J. M. et al. High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle. Oncotarget 5, 4694\u20134708 (2014).","journal-title":"Oncotarget"},{"key":"52714_CR68","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1042\/BJ20091578","volume":"427","author":"V Papadopoulou","year":"2010","unstructured":"Papadopoulou, V., Postigo, A., Sanchez-Tillo, E., Porter, A. C. & Wagner, S. D. ZEB1 and CtBP form a repressive complex at a distal promoter element of the BCL6 locus. The Biochemical journal 427, 541\u2013550 (2010).","journal-title":"The Biochemical journal"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52714-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52714-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52714-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T15:46:00Z","timestamp":1671291960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52714-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["52714"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-52714-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,11]]},"assertion":[{"value":"10 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.D. Delgado and A. Batlle-Lopez\u2019s work has been funded by Celgene. The other authors declare no potential competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16495"}}